ES2058573T3 - Il2 humana recombinante no glicosilada en forma reducida, su procedimiento de obtencion y su aplicacion como medicamento. - Google Patents

Il2 humana recombinante no glicosilada en forma reducida, su procedimiento de obtencion y su aplicacion como medicamento.

Info

Publication number
ES2058573T3
ES2058573T3 ES89402124T ES89402124T ES2058573T3 ES 2058573 T3 ES2058573 T3 ES 2058573T3 ES 89402124 T ES89402124 T ES 89402124T ES 89402124 T ES89402124 T ES 89402124T ES 2058573 T3 ES2058573 T3 ES 2058573T3
Authority
ES
Spain
Prior art keywords
obtaining
application
recombinant human
glycosilated
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89402124T
Other languages
English (en)
Inventor
Danielle Lando
Philippe Riberon
Pierre Yves Abecassis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Application granted granted Critical
Publication of ES2058573T3 publication Critical patent/ES2058573T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UNA IL2 HUMANA RECOMBINANTE, NO GLICOSILADA, CUYAS TRES CISTEINAS EN POSICION 58, 105 Y 125 ESTAN BAJO FORMA REDUCIDA, Y QUE MANIFIESTA UNA ACTIVIDAD BIOLOGICA COMPARABLE A LA DE LA IL2 OXIDADA QUE TIENE LA MISMA SECUENCIA Y QUE TIENE UN PUENTE DISULFURO EN POSICION 58-105, SU PROCEDIMIENTO DE OBTENCION Y SU APLICACION COMO MEDICAMENTO.
ES89402124T 1988-07-28 1989-07-26 Il2 humana recombinante no glicosilada en forma reducida, su procedimiento de obtencion y su aplicacion como medicamento. Expired - Lifetime ES2058573T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8810184A FR2635527B1 (fr) 1988-07-28 1988-07-28 Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament

Publications (1)

Publication Number Publication Date
ES2058573T3 true ES2058573T3 (es) 1994-11-01

Family

ID=9368873

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89402124T Expired - Lifetime ES2058573T3 (es) 1988-07-28 1989-07-26 Il2 humana recombinante no glicosilada en forma reducida, su procedimiento de obtencion y su aplicacion como medicamento.

Country Status (21)

Country Link
US (2) US5874076A (es)
EP (1) EP0353150B1 (es)
JP (1) JP3016793B2 (es)
KR (1) KR0131070B1 (es)
CN (1) CN1036532C (es)
AT (1) ATE110783T1 (es)
AU (1) AU624625B2 (es)
DE (1) DE68917826T2 (es)
DK (1) DK370489A (es)
ES (1) ES2058573T3 (es)
FI (1) FI96209C (es)
FR (1) FR2635527B1 (es)
HU (1) HU207099B (es)
IE (1) IE64232B1 (es)
IL (1) IL90975A (es)
MX (1) MX16912A (es)
NZ (1) NZ230111A (es)
PT (1) PT91295B (es)
RU (1) RU2105011C1 (es)
UA (1) UA26846C2 (es)
ZA (1) ZA895419B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
FR2668368B1 (fr) * 1990-10-30 1995-03-10 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
ES2107449T3 (es) * 1990-11-23 1997-12-01 Roussel Uclaf Procedimiento de preparacion de una proteina elegida entre las citoquinas, que comprende al menos un puente disulfuro intramolecular por oxidacion, a un ph inferior a 5,0 de la proteina recombinante reducida correspondiente.
FR2671728B1 (fr) * 1991-01-17 1995-01-20 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des pneumathorax.
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US6470207B1 (en) * 1999-03-23 2002-10-22 Surgical Navigation Technologies, Inc. Navigational guidance via computer-assisted fluoroscopic imaging
US20050203578A1 (en) * 2001-08-15 2005-09-15 Weiner Michael L. Process and apparatus for treating biological organisms
RU2372356C2 (ru) * 2003-08-07 2009-11-10 Займоджинетикс, Инк. Полипептид с антивирусной активностью, его получение и применение
MX2020005041A (es) 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
IL294659A (en) 2020-01-14 2022-09-01 Synthekine Inc Methods and preparations of il2 skewed mutants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) * 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
US4654830A (en) * 1984-11-27 1987-03-31 Monolithic Memories, Inc. Method and structure for disabling and replacing defective memory in a PROM
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
JPH0829113B2 (ja) * 1986-11-11 1996-03-27 武田薬品工業株式会社 ヒトインタ−ロイキン−２の製造法

Also Published As

Publication number Publication date
HU207099B (en) 1993-03-01
EP0353150B1 (fr) 1994-08-31
AU3902489A (en) 1990-02-01
FI893587A (fi) 1990-01-29
DK370489A (da) 1990-01-29
RU2105011C1 (ru) 1998-02-20
ZA895419B (en) 1990-09-26
US5874076A (en) 1999-02-23
JPH02209896A (ja) 1990-08-21
CN1036532C (zh) 1997-11-26
FI96209B (fi) 1996-02-15
IE892443L (en) 1990-01-28
CN1042377A (zh) 1990-05-23
DE68917826D1 (de) 1994-10-06
IL90975A0 (en) 1990-02-09
IE64232B1 (en) 1995-07-26
MX16912A (es) 1993-10-01
HUT51647A (en) 1990-05-28
FI96209C (fi) 1996-05-27
FR2635527B1 (fr) 1992-06-12
AU624625B2 (en) 1992-06-18
JP3016793B2 (ja) 2000-03-06
UA26846C2 (uk) 1999-12-29
EP0353150A1 (fr) 1990-01-31
PT91295B (pt) 1995-03-01
KR0131070B1 (ko) 1998-04-11
NZ230111A (en) 1992-04-28
PT91295A (pt) 1990-02-08
FR2635527A1 (fr) 1990-02-23
DE68917826T2 (de) 1995-01-12
KR900001854A (ko) 1990-02-27
US5814314A (en) 1998-09-29
DK370489D0 (da) 1989-07-27
FI893587A0 (fi) 1989-07-27
ATE110783T1 (de) 1994-09-15
IL90975A (en) 1994-11-28

Similar Documents

Publication Publication Date Title
FI905956A0 (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
ATE134507T1 (de) Mikroverkapseltes sonnenschutzmittel, das verfahren zur herstellung, kosmetische und pharmazeutische zubereitungen mit mikrokapseln und verwendung derselben
FR2710527B1 (fr) Nouvelles compositions cosmétiques et dermatologiques associant céramides et acide linoléique, leur préparation.
DE59101397D1 (de) O-glycosyliertes ifn-alpha.
DE3882593D1 (de) Polypeptid und dessen herstellung.
ATA285187A (de) Substituierte alpha-aminosaeuren, ihre herstellung und diese enthaltende arzneimittel
DE68912459D1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
AT380202B (de) Material zur herstellung von artikeln zur abstuetzung des kopfes oder von gliedmassen des menschen oder von tieren, sowie aus diesem material hergestellte artikel
ES2058573T3 (es) Il2 humana recombinante no glicosilada en forma reducida, su procedimiento de obtencion y su aplicacion como medicamento.
DE69219590D1 (de) BPC-Peptide, deren Herstellung und Verwendung
ATE71658T1 (de) Verfahren zur herstellung von humanlysozym.
DE3882135D1 (de) Verwendung von melatonin oder seine derivate zur herstellung von arzneimitteln, die gegen alterskrankheiten wirksam sind.
DE3650715D1 (de) Verwendung von menschlichem Interferon-Beta 2A für die Herstellung von Medikamenten
DE69106407D1 (de) Verfahren zur Herstellung von rekombinantem menschlichem gamma-Interferon ohne Cystein und ohne Methionin am N-Terminal.
ATE40888T1 (de) Verfahren zur herstellung von ranitidin oder saeureadditionssalze davon und zwischenprodukte fuer diese herstellung.
ATE95234T1 (de) Verfahren zur herstellung von proteinen mit fviii aktivitaet und/oder fviii derivate.
DE3687448D1 (de) Verwendung von 6h-7,8-dihydrothiapyrano(3,2d)pyrimidinen zur herstellung von arzneimitteln zur verwendung als hypoglykaemische mittel oder als abmagerungsmittel fuer fettsuechtige patienten.
ATA270188A (de) Enantiomerenreine zwischenprodukte, deren herstellung und deren verwendung zur herstellung von enantiomerenreinem disparlure
ATE51154T1 (de) Antithrombogenes, nichtcalcifizierendes material und ein verfahren zur herstellung von gegenstaenden fuer medizinische zwecke.
ATE92106T1 (de) Polypeptid und dessen herstellung.
ATE80289T1 (de) Mittel zur kosmetischen oder pharmazeutischen verwendung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 353150

Country of ref document: ES